---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-003169"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:35:33.532520+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte announces $35M convertible preferred financing and tender offer for up to 7.75M shares at $3.25

## Summary
- Raises ~$35M via sale of 35,000 Series B convertible preferred shares and warrants to existing investors.
- Preferred stock convertible at $4.00/share; warrants exercisable at $4.00/share for up to 8.75M shares, expiring in 5 years.
- Commences cash tender offer for up to 7,750,000 common shares at $3.25/share, expiring June 9, 2023.
- Tender offer funded from cash on hand; CEO cites no definitive timeframe for pancreatic cancer asset.
- Preferred shares carry 4% annual dividend, redeemable monthly starting Nov 9, 2023; subject to Nasdaq approval.

## SEC filing metadata
- accession: 0001683168-23-003169
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316823003169/0001683168-23-003169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316823003169/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-003169
- JSON: https://secwatch.observer/filing/0001683168-23-003169.json
- Plain text: https://secwatch.observer/filing/0001683168-23-003169.txt

## Key facts
- Material Agreements
  PharmaCyte Biotech, Inc. entered into Engagement Letter with Katalyst Securities LLC valued at cash fee equal to 6% of gross proceeds (effective 2023-05-09).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Katalyst Securities LLC
  - Value: cash fee equal to 6% of gross proceeds
  - Effective: 2023-05-09
  source text: In connection with the Private Placement, pursuant to an Engagement Letter, dated May 9, 2023, between the Company and Katalyst Securities LLC (the “Placement Agent”), the Company has agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from any sale of securities in the Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316823003169/0001683168-23-003169-index.htm
- Material Agreements
  PharmaCyte Biotech, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds of approximately $35 million (effective 2023-05-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: aggregate gross proceeds of approximately $35 million
  - Effective: 2023-05-09
  source text: On May 9, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 35,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 8,750,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a conversion price of $4.00 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 8,750,000 shares of Common Stock (the “Warrants”) (collectively, the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316823003169/0001683168-23-003169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.